|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01858 CHUNLI MEDICAL
Nominal 
15.480 0.000 (0.000%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 487,596 | 28.271% | 805,857 | 1,208,524 | 1,201,604 | 1,108,140 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (35,034) | 451.444% | (28,529) | (15,412) | (20,777) | (27,290) | |
| Profit / (Loss) on Disposal | 4 | -90.187% | 39 | 4 | 25 | 15 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 127,313 | 53.259% | 131,599 | 305,906 | 336,880 | 367,379 | |
| Taxation | (12,831) | 212.269% | (6,938) | (28,088) | (29,161) | (45,018) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (12) | -- | 327 | 6 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 114,469 | 44.850% | 124,988 | 277,824 | 307,719 | 322,361 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (6,743) | -25.179% | (17,068) | (16,582) | (20,175) | (9,642) |
| Depreciation & Amortisation | 20,011 | 7.299% | 37,677 | 34,655 | 30,162 | 18,526 |
| Directors' Emoluments | -- | -- | 3,197 | 3,938 | 3,780 | 3,444 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 30.000 | 42.857% | 33.000 | 72.000 | 80.000 | 93.000 |
| DPS (cts) | 0.000 | -- | 13.200 | 36.200 | 31.300 | 13.000 |
| Dividend Payout Ratio (%) | -- | -- | 40.000% | 50.278% | 39.125% | 13.978% |
| Cash flow per share ($) | -- | -- | (0.005) | 1.334 | 0.107 | 0.476 |
| NBV per share ($) | 7.608 | -- | 7.368 | 7.502 | 7.077 | 6.425 |
| Remarks: | Real time quote last updated: 24/09/2025 08:26 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 114,469 |
| %Change | 44.850% |
| EPS / (LPS) | RMB 0.300 |
| NBV Per Share (¥) | RMB 7.608 |